Immunotherapy: Recent Advances and Its Future as a Neoadjuvant, Adjuvant, and Primary Treatment in Colorectal Cancer
Open accessThe DOI matches its Crossref record; 99 of the 99 references it cites were found in a registry or an index.
Abstract
Immunotherapy in colorectal cancer (CRC) has made great strides within the past decade. Immune checkpoint inhibitors are a class of immunotherapy and have been shown to greatly improve patient outcomes in mismatch repair-deficient (dMMR) CRC. Now, they are part of the standard of care for this subset of CRC. Because of this, there has been a growing interest in the efficacy and timing of immunotherapy for other subsets of CRC, including locally advanced, metastatic, and microsatellite stable (MSS). In this review, we aim to examine the three main classes of immunotherapy for CRC—immune checkpoint inhibitors (ICIs), adoptive cell transfer therapy (ACT), and tumor vaccines—and discuss the most recent advances and future directions for each.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“This subset of CRC exhibits high immunogenicity due to increased mutational burden, inducing high immune cell infiltration, particularly from tumor-infiltrating lymphocytes [37,38].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · cited 1×
“CTLA-4 is expressed on some T cells, such as regulatory T cells [5], which play a role in maintaining self-tolerance [6], as well as activated CD4+ T cells [7], which play a role in generating an antitumor response from the immune system [8].”
BackgroundSafety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · cited 1×
“In the landmark trial, it was demonstrated that one in every four to five patients with melanoma, renal cell carcinoma, or non-small-cell lung cancer had significant responses to anti-PD-1 treatment [11].”
BackgroundGut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812 · cited 2×
“Additionally, there are studies indicating that the microbiome [53,54] and diet [55] can alter tumor responses to ICIs.”
BackgroundBoland, C. R., Thibodeau, S. N., Hamilton, S. R., Sidransky, D., Eshleman, J. R., Burt, R. W., Meltzer, S. J., Rodrı́guez-Bigas, M. A., Fodde, R., Ranzani, G. N., et al. (1998) · PubMed · Cited by 4,087
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
Sivan, A., Corrales, L., Hubert, N., Williams, J. B., Aquino-Michaels, K., Earley, Z. M., Benyamin, F. W., Man Lei, Y., Jabri, B., Alegre, M.-L., et al. (2015) · Science · doi:10.1126/science.aac4255 · Cited by 3,888 · cited 2×
“Additionally, there are studies indicating that the microbiome [53,54] and diet [55] can alter tumor responses to ICIs.”
BackgroundTumor mutational burden and response rate to PD-1 inhibition
Yarchoan, M., Hopkins, A., & Jaffee, E. M. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1713444 · Cited by 3,230 · cited 1×
“Additionally, pMMR CRC has a lower mutational burden and fewer antigens that can be detected by cytotoxic T cells, which are associated with a poor response to ICIs [43,46].”
BackgroundPembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer
André, T., Shiu, K.-K., Kim, T. W., Jensen, B. V., Jensen, L. H., Punt, C., Smith, D., Garcia-Carbonero, R., Benavides, M., Gibbs, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2017699 · Cited by 3,099 · cited 3×
“Almost 50% of patients were progression-free at 24 months and were able to discontinue treatment [22].”
BackgroundInfluentialGrothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61900-x · Cited by 2,895
Marabelle, A., Fakih, M., Lopez, J., Shah, M., Shapira-Frommer, R., Nakagawa, K., Chung, H. C., Kindler, H. L., Lopez-Martin, J. A., Miller, W. H., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30445-9 · Cited by 2,552 · cited 1×
“In the KEYNOTE-158 trial, there were clinically meaningful responses to Pembrolizumab across patients with high TMB, but interestingly, MSI-H status did not account entirely for the clinical benefit seen [29].”
Background
Cited by
Abedizadeh, R., Majidi, F., Khorasani, H. R., Abedi, H., & Sabour, D. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10158-3 · Cited by 293
“The purpose of these vaccines is to create an immune response against tumor antigens, and they are usually administered together with an adjuvant or combined with other immunotherapy methods to increase efficiency [160].”
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
“The most common ICIs are PD-1 inhibitors (e.g., pembrolizumab, nivolumab) and CTLA-4 inhibitors (e.g., ipilimumab), which activate T cells to induce an antitumor response from the immune system (Figure 2) [38].”
Magnetic Particle Imaging: From Tracer Design to Biomedical Applications in Vasculature Abnormality
Xie, X., Zhai, J., Zhou, X., Guo, Z., Lo, P., Zhu, G., Chan, K. W. Y., & Yang, M. (2023) · Advanced Materials · doi:10.1002/adma.202306450 · Cited by 62
Kaviarasan, V., Das, A., Deka, D., Saha, B., Banerjee, A., Sharma, N. R., Duttaroy, A. K., & Pathak, S. (2024) · International Journal of Colorectal Disease · doi:10.1007/s00384-024-04790-w · Cited by 55
Plant Foods and Their Bioactives as Dietary Enhancers for Colon Cancer Treatment with 5-Fluorouracil
Yang, Z., Céspedes, C. L., Yang, Z., Bakar, M. Z. A., Chan, K. W., & Deng, X. (2025) · Food Reviews International · doi:10.1080/87559129.2024.2446366 · Cited by 39
“[5,48,49] Chemotherapy is essential in treating CC across all stages, particularly in advanced stages, as it targets and destroys cancer cells that may not be removed by surgery.”
Recent research progress and clinical status of immunotherapy for colorectal cancer
Huo, Z., Liu, G., & Li, J. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.06.089 · Cited by 36
Beyond Barriers: Achieving True Equity in Cancer Care
Chin, Z. S., Ghodrati, A., Foulger, M., Demirkhanyan, L. H., & Gondi, C. S. (2025) · Current Oncology · doi:10.3390/curroncol32060349 · Cited by 23
“Immunotherapy combined with biologics and other curative treatments may be more effective when administered as primary therapy in patients with minimal cancer burden [114].”
Can immunotherapy reinforce chemotherapy efficacy? a new perspective on colorectal cancer treatment
He, X., Lan, H., Jin, K., & Liu, F. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1237764 · Cited by 23
“In addition to T cells, under the in fl uence of TME, DCs acquire different functional and phenotypic characteristics, which leads to their non-functionality in anti-tumor responses and even suppression of immune responses (182, 183).”
BackgroundChen, Y., Qi, Y., Jiang, Y., Li, Y., Yang, S., Wang, L., Li, M., Chai, K., & Wang, Y. (2025) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2025.118317 · Cited by 18
Jurjus, A. R., Masri, J. E., Ghazi, M., Ayoubi, L. M. E., Soueid, L., Geagea, A. G., & Jurjus, R. A. (2024) · Nutrients · doi:10.3390/nu16081236 · Cited by 23
“There are no conclusive results concerning the role of neutrophils in IBD, yet some studies found that colitis could be reduced with anti-neutrophil antibodies, while other studies showed that colitis is aggravated after depleting the number of neutrophils by using antiserum or by inhibiting their…”
BackgroundKeivany, M. R., Asrami, E. S., Besharatloo, M., Latifi, H., & Barjasteh, A. H. (2026) · Cancer Cell International · doi:10.1186/s12935-026-04177-7 · Cited by 18
Clerick, J., Oosterwyck, A. V., & Carton, S. (2024) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2024.100807 · Cited by 15
Update on Mucoadhesive Approaches to target Drug Delivery in Colorectal Cancer
Kanojia, N., Thapa, K., Verma, N., Rani, L., Sood, P., Kaur, G., Dua, K., & Kumar, J. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.104831 · Cited by 12
Nanobody-Directed CEA-Targeting CAR T Cells Eliminate Gastrointestinal Cancer Xenografts
Feng, Z., Zhang, X., Peng, Z., Aghamajidi, A., Wu, Y., & Hua, X. (2025) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-24-0137 · Cited by 11
Hao, Q., Zhang, M., Wu, Y., Guo, Y., Zheng, Y., Wu, L., Li, F., & Wang, Z. (2023) · Scientific Reports · doi:10.1038/s41598-023-45164-6 · Cited by 9
Chen, Y., Ohara, T., Hamada, Y., Wang, Y., Tian, M., Noma, K., Tazawa, H., Fujisawa, M., Yoshimura, T., & Matsukawa, A. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04067-3 · Cited by 9
“While patients with MSI-high CRC exhibit favorable responses to immunotherapy, including immune checkpoint inhibitors (ICIs), those with microsatellite stable (MSS) CRC, constituting the majority, are unresponsive to ICIs [3].”
Lv, M., Guo, S., Zhang, X., Zou, Y., Chen, Q., Zang, C., Huang, S., Hu, Y., Wang, Y., Wang, Q., et al. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110918 · Cited by 9
Chen, J.-T., Zhou, Y., Han, T.-R., Wei, J.-L., & Qiu, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1269341 · Cited by 11
“Moreover, there is evidence showing that patients with dMMR/ MSI-H CRC can obtain high reactivity of ICIs therapy, but for a majority of patients with pMMR or MSS, the clinical bene fi ts from ICIs are generally minimal (12, 14, 17, 18, 32 – 37).”
BackgroundAdvances in KRAS mutation inhibition in metastatic colorectal cancer
Wu, C., Li, W., Chen, M., Zhang, Q., Xu, T., Ma, Y., Liu, W., Wang, Z., Wang, X., Li, J., et al. (2023) · Holistic Integrative Oncology · doi:10.1007/s44178-023-00032-1 · Cited by 7
“ACT is a form of immunotherapy in which a patient’s own immune cells reactive to neoantigens are expanded in vitro and then re-introduced into the patient, ultimately eliciting an immune response against any cancer cells expressing the targeted antigens [59].”
BackgroundZhai, X., Chen, B., Hu, H., Deng, Y., Chen, Y., Hong, Y., Ren, X., & Jiang, C. (2024) · Cancer Medicine · doi:10.1002/cam4.7315 · Cited by 6
“…response, particularly by blocking the combination of activated T cells and PD-L1, which otherwise compromises the immunity in patients with CRC. 33,34 Nevertheless, the clinical outcome of ICIs in patients with advanced CRC remains unsatisfactory owing to congenital ICI resistance or no response…”
BackgroundMethodAdvances in the Use of Immune Checkpoint Inhibitors for Colorectal Cancer Treatment
Li, J., Fu, T., Zhu, W., Liang, J., Qiu, Y., Li, K., Yang, J., Tong, Y., & Cai, H. (2025) · OncoTargets and Therapy · doi:10.2147/ott.s551204 · Cited by 5
“This subgroup of patients is characterized by high tumor mutational burden, abundant tumor neoantigens, and increased T-cell infiltration, making them ideal candidates for immunotherapy, with some patients achieving durable survival (5).”
Zhang, H., Wang, R., Yu, T., Yu, D., Song, C., Ma, B., & Li, J. (2024) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-23-863 · Cited by 5
“For patients who have been treated aggressively but still have a high-risk score, monitoring can be strengthened, postoperative management can be enhanced, and even immunotherapy can be considered to improve the patient’s prognosis (34) .”
Jafarlou, M., Jafarlou, V., Nouri, S., Alizadeh, N., Tabrizi, Z. A., Iravani, M., Ghorbaninezhad, F., Shakiba, D., & Baradaran, B. (2026) · Cancer Cell International · doi:10.1186/s12935-026-04385-1 · Cited by 3
“Recent clinical studies are evaluating the effectiveness of PD-1 and CTLA-4 inhibition in combination with supplementary therapies, such FOLFOX plus bevacizumab (NCT05627635) or panitumumab (NCT03442569) [60, 83].”
Xie, Z., Peng, N., Pan, Z., Feng, Y., Wu, Y., Yang, Y., Li, R., & Zhao, L. (2025) · Cancer Gene Therapy · doi:10.1038/s41417-025-00964-y · Cited by 2
The current status of immunotherapy in colorectal cancer: A systematic review
Cholewa, H., Guerrero-Antolino, P., David, Q., Jorge, S.-M., Frasson, M., & Lorente, B. F. (2025) · Cirugía Española · doi:10.1016/j.cireng.2025.800225 · Cited by 2
Huang, C.-Y., Qiu, X.-S., Lu, S.-W., Wang, Y., Wu, Y., Xu, J.-D., Wen, X.-Y., Wu, C.-H., Lin, J.-L., & Wu, X.-B. (2026) · Current Problems in Surgery · doi:10.1016/j.cpsurg.2026.101995 · Cited by 2
Advancements in immunotherapy research for colorectal cancer based on microsatellite status
Shuai, X. I. A. O., XiGuang, C. H. E. N., & XuYu, Z. U. (2023) · Scientia Sinica Vitae · doi:10.1360/ssv-2023-0103 · Cited by 2
The Potential Role of Intestinal Stem Cells and Microbiota for the Treatment of Colorectal Cancer
Arjmand, B., Alavi-Moghadam, S., Faraji, Z., Pasha, M. A., Jalaeikhoo, H., Rajaeinejad, M., Nikandish, M., Faridfar, A., Mafi, A. R., Rezaei–Tavirani, M., et al. (2024) · Advances in experimental medicine and biology · doi:10.1007/5584_2024_803 · Cited by 2
Wang, J., Lu, Y., Li, F., & Huang, M.-L. (2024) · World Journal of Clinical Oncology · doi:10.5306/wjco.v15.i8.968 · Cited by 2
Liver Transplantation for Non-hepatocellular Carcinoma: The Role of Immune Checkpoint Inhibitors
Bahrami, P., Zein, M. A., Eid, A. H., & Sahebkar, A. (2025) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2025.102558 · Cited by 1
Microbiota-Targeted Therapies for Colorectal Cancer: Current Challenges and Future Directions
Sadhana, H., Santosh, K. A., Balaji, P. G., & Yadav, A. K. (2025) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-031-86065-2_17 · Cited by 1
Tang, Y., Cui, W., Shi, S., Sun, L., Yan, L., Wei, B., Liu, F., Xi, Y., Xie, B., & Zhang, Z. (2025) · JCO Precision Oncology · doi:10.1200/po-25-00010 · Cited by 1
FSTL1 is a prognostic marker and promotes invasion and metastasis of colon cancer
Zhong, C., Cheng, Z., Shu, Y., Yang, X., Hu, J., He, L., Li, X., Chen, X., & Liu, Y. (2025) · Discover Oncology · doi:10.1007/s12672-025-03989-9 · Cited by 1
Wang, Z., Cai, X., Pei, G., Cheng, X., Tian, L., Zhou, Y., Shi, W., Yang, J., Dong, J., & Li, Y. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08189-9 · Cited by 1
“%) patients with microsatellite stable (MSS) or microsatellite instability-low (MSI-L) show minimal response [3, 4].”
Genomics – The barriers are falling
Clark, S. (2024) · Colorectal Disease · doi:10.1111/codi.17097
“It is increasingly recognised that the beneficiaries of this are not just those with Lynch syndrome associated cancer, but potentially all patients with mismatch repair deficient tumours [3].”
Diagnostic Advances and Novel Therapeutics in Peritoneal Metastasis
Sigler, G., Murtha, J. A., & Varley, P. R. (2025) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2024.12.005
Multimodal Treatment of Recurrence and Distant Metastases of Colorectal Cancer
(2025) · Frontiers research topics · doi:10.3389/978-2-8325-6045-7
Ranjan, R., Kumar, A., Kumar, V., Mahato, B. K., Sarkar, A., Yadav, R. K., Gond, V., Nagaraja, S., & Pal, R. R. (2026) · Immunological Investigations · doi:10.1080/08820139.2026.2613047 · Cited by 1
“The progress of immunotherapy in colorectal cancers began around 2012 with a clinical trial supported by Bristol-Myers Squibb, the firm that was responsible for the growth of the anti-PD-1 antibody, as shown in Figure 2 (Yu et al., 2023).”
Advances in Neoadjuvant Therapy for Colorectal Cancer
练, 达. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.1652038
Sun, M., Jiang, H., Yang, J., Tang, R., 刘庆祝, Peng, Y., Zhao, J., Qiu, L., Lin, J., & Jiang, H. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.110156
Metadata
- Authors
- Yu, I., Dakwar, A., & Takabe, K.
- Affiliations
- Roswell Park Comprehensive Cancer Center (US)
- Corresponding author
- Takabe, Kazuaki
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2023-01-08
- Volume
- 12
- Issue
- 2
- Pages
- 258
- ISSN
- 2073-4409 (ISSN-L)
- PMC
- PMC9856401
- OpenAlex
- W4313825882
- Cited by
- 40
- References
- 99
- Citations by year
- 2026: 7 · 2025: 16 · 2024: 8 · 2023: 9
- FWCI
- 1.29
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cells (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institutes of Health, USA (P30 CA016056/CA/NCI)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- colorectal cancer, immunotherapy, immune checkpoint inhibitors, mismatch repair deficiency, neoadjuvant therapy, adjuvant therapy, primary treatment, metastatic colorectal cancer, locally advanced colorectal cancer, microsatellite stable colorectal cancer, adoptive cell transfer, cancer vaccines
- MeSH terms
- Immune Checkpoint Inhibitors, Adjuvants, Immunologic, Adjuvants, Pharmaceutic, Brain Neoplasms, Humans, Immunotherapy, Neoplastic Syndromes, Hereditary, Colorectal Neoplasms, Neoadjuvant Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.